N18A Stock Overview
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nemaura Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$1.04 |
| 52 Week Low | US$0.084 |
| Beta | -0.096 |
| 1 Month Change | 0% |
| 3 Month Change | -40.72% |
| 1 Year Change | -85.89% |
| 3 Year Change | -98.22% |
| 5 Year Change | n/a |
| Change since IPO | -98.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| N18A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.5% |
| 1Y | -85.9% | -4.9% | 5.4% |
Return vs Industry: N18A underperformed the German Medical Equipment industry which returned 3.7% over the past year.
Return vs Market: N18A underperformed the German Market which returned 5.1% over the past year.
Price Volatility
| N18A volatility | |
|---|---|
| N18A Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: N18A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine N18A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 36 | Faz Chowdhury | nemauramedical.com |
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.
Nemaura Medical Inc. Fundamentals Summary
| N18A fundamental statistics | |
|---|---|
| Market cap | €2.39m |
| Earnings (TTM) | -€9.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs N18A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N18A income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.48m |
| Gross Profit | -US$1.48m |
| Other Expenses | US$9.17m |
| Earnings | -US$10.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -110.2% |
How did N18A perform over the long term?
See historical performance and comparison